Typherix + NVGH Vi-CRM197
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Typhoid Fever
Conditions
Typhoid Fever
Trial Timeline
May 1, 2010 → Nov 1, 2010
NCT ID
NCT01123941About Typherix + NVGH Vi-CRM197
Typherix + NVGH Vi-CRM197 is a phase 1 stage product being developed by Novartis for Typhoid Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01123941. Target conditions include Typhoid Fever.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01123941 | Phase 1 | Completed |
Competing Products
7 competing products in Typhoid Fever
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 77 |
| Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine | Novartis | Phase 2 | 52 |
| NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine | Novartis | Phase 2 | 52 |
| NVGH Vi-CRM197 | Novartis | Phase 2 | 52 |
| Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine | Novartis | Phase 2 | 52 |
| Vivotif | Bavarian Nordic | Pre-clinical | 20 |
| Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4) | Emergent BioSolutions | Phase 2 | 44 |